Organ Transplantation, German Index for Stem Cell Transplantation, Literature). RESULTS: Bavarian demand for blood products of approximately 2,850 units per workday (750,000 units per year) was estimated. Potential blood donators add up to approximately 8,474 million people. Assuming a donation rate of 3% an approx. number of 250,000 donators exist. Most active segment of donators is between 32-56 years. It will be affected by the demographic shift, means a declining population of approximatelt 425,000 people in this segment. Stem cell transplantations (+50% in the last 7 years) and organ transplantations (+15% in 2005) lead to an increasing demand of blood products. Statistical data show an increasing life expectancy of 5 years until 2050 (male 81.1/female 86.6 years) entailing higher cancer incidence rates (+50% until 2050) affecting blood consumption (20% of all blood products are used in cancer therapies). The German blood market volume for the year 2005 is estimated to be €500 mill. For the Bavarian sub-segment a value of €75 million can be deducted. CONCLUSION: Further research and survey will be necessary to derive strategic recommendations for the blood market participants. Then a dynamic population model will be developed to project future effects on blood demand and supply. 
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METHODS:
The process involved potential users of HTA information namely 1) public health insurers; 2) national health policy makers; and 3) HITAP public funding organizations. In December 2006, these key players were invited to submit the topics needed to be assessed based on their considerations. The submitted topics were reviewed and prioritised by HITAP researchers in January 2007 using several preset criteria. Furthermore, a consultation workshop was conducted and the representatives from those organisations submitted the HTA topics provide justifications and prioritize their own list of top ten HTA topics needed to be assessed in 2007. Results from each organisation were analysed and the final list made by workshop participants were compared with the list made by HITAP researchers. RESULTS: Fifty-one topics were submitted from ten organisations. However, only 29 distinct HTA topics were met inclusion criteria and then included in the priority setting process. Most topics were pharmaceuticals (51%), medical procedures (24%), medical devices (15%) and health policy (10%). At final, six out of ten topics selected by HITAP researchers were the same as those made by the representatives from public health authorities. CONCLUSION: Findings from this study illustrated the possibility to make HTA topic selection process to be systematic, transparent and participatory, which would eventually increase the usefulness and credibility of HTA. 
PHP4 CANADIAN COMPETION DURING A U.S. GENERIC DRUG'S 180-DAY EXCLUSIVITY PERIOD
Richards KM, Shepherd MD University of Texas at Austin, Austin, TX, USA OBJECTIVES: To compare Canadian brand and generic drug prices and U.S. generic drug prices for ten months following U.S. brand patent expiration and to bring attention to a growing source of competition during a generic company's 180-day marketing exclusivity period. METHODS: The Canada/U.S. Internet Pharmacy Drug Price Database contains weekly prices since January 2005 of more than 50 prescription medications from eight Canadian and five U.S. on-line pharmacies. Ten months of pricing data ($US) were extracted and compared for the Canadian and U.S. brand and generic versions of sertraline and simvastatin following U.S. patent expiration in 2006. RESULTS: During the first six months after U.S. patent expiration, the average prices of brand and generic sertraline 100 mg from Canadian on-line pharmacies were 11.4 and 45.5 percent less, respectively, than the price of generic sertraline from U.S. on-line pharmacies. Canadian brand and generic simvastatin 20 mg were 32.2 and 60.4% less expensive, respectively, than U.S. generic simvastatin. At the tenth month post U.S. patent expiration, the average price of the Canadian brand product exceeded that of the U.S. generic product for both sertraline (by 15.8%) and simvastatin (by 35.2%). However, Canadian generic products were still less expensive than U.S. generic products (sertraline, 34.3% less; simvastatin, 41.6% less). Prices for U.S. generic sertraline and simvastatin dropped an average of five and 14 percent monthly, respectively, after the exclusivity period. CONCLUSION: U.S. generic drugs can be more expensive than both brand and generic Abstracts A361 products from Canadian on-line pharmacies during a 180-day exclusivity period. A decrease of U.S. generic prices is expected following this period as more products enter the market, and U.S. prices over time typically fall below those of Canadian generic prices. The availability of Canadian drugs to U.S. residents increases the short-run competition to independent and authorized generic companies during exclusivity periods.
PHP5 DOES ENTRY OF GENERIC DRUGS ALWAYS RESULT IN COST-CONTAINMENT? THE HUNGARIAN EVIDENCE
Kalo Z 1 , Herczeg B 2 , Katona K 3 1 Eotvos Lorand University, Budapest, Hungary, 2 Semmelweis University, Budapest, Hungary, 3 Szinapszis Market Research and Consulting Ltd, Budapest, Hungary OBJECTIVES: Patent protection is the key condition of pharmaceutical innovation. After patent expiry utilisation of generic drugs decreases health care expenditure, and alleviates the scarcity of health care budget. Our objective was to measure the ability of generics to reduce the pharmaceutical expenditure in the Hungarian market. METHODS: Drug utilisation records of 10 substances with patent expiry between 2001-2006 have been compared 12 months before and after the entry of the first generic product. RESULTS: Although entry of generics reduced daily therapeutic costs, the increase in volume sales outbalanced the potential savings in drug budget. Overall generic drugs increased the expenditure of a subtance with no patent protection by 30.1%, the public reimbursement by 25.7%, and unit sales by 21.0%. In 5 cases the originator successfully converted the majority of patients to a non-substitutable formulation. When we limited our analysis to substances with no restrictions in generic substitution, public reimbursement and unit sales were still increased by 21.1%, 17.4% and 18.6% respectively. CONCLUSION: The entry of generic drugs in Hungary-as opposed to the international experience-did not reduce pharmaceutical expenditure between [2001] [2002] [2003] [2004] [2005] [2006] , what is more, generics increased the tendency of pharmaceutical spending. The main reason for this failure was the inappropriate generic drug policy. The lack of delisting, the low generic price erosion, the lack of incentives to physicians and pharmacists to switch patients to generic products, the branded promotional campaigns by generic manufacturers, and the conversion of patients to patented formulations by original manufacturers contributed to the inefficiency of the generic programme in Hungary.
PHP6 NETWORKING TOWARDS FUNCTIONAL POLICY-TOOLS: CAN CONDITIONAL REIMBURSEMENT OF DRUGS LEAD TO EFFICIENT AND EFFECTIVE DRUG USE?
Niezen MGH, De Bont A, Stolk EA Erasmus Medical Center, Rotterdam, The Netherlands OBJECTIVES: Policymakers increasingly use a policy of "conditional reimbursement" of pharmaceutical care in order to obtain more control over drug prescriptions and increase patient, physician and payer compliance to drug use. Our objective was to resolve which factors determine the efficient functioning of conditional reimbursement as a policy-tool. METHODS: Drawing on 65 interviews and two focus-group sessions with representatives of patients, physicians, pharmacists, health insurers, pharmaceutical industry, and policymakers, we studied stakeholders' perspectives on the general functioning of conditional reimbursement as a policy tool, with particular attention being paid to five drugs. The participants' data was completed and validated by way of document analysis. RESULTS: Effectiveness of conditional reimbursement depends on how it has been implemented and/or how stringently regulations are enforced. The data revealed controversies concerning the policy-tool's transparency, legitimacy, feasibility and commitment on the part of the stakeholders. These controversies most often were caused by a lack of coordination and cooperation within the network of drug reimbursement. Yet, a good network in which coordination and cooperation are facilitated appeared a necessary, but sometimes not sufficient condition. Case-specific characteristics have the potential to make or break the networks in which the instrument is embedded and often are beyond control of the policymakers. CONCLUSION: Problems occur when the conditional reimbursement policy fails to connect to the range of diverse interests of those carrying the instrument to its effect. Conditional reimbursement has the potential to work if a more or less stable network, in which cooperation and coordination are organized, is available or can be created. Moreover, policymakers should take into account whether case-specific characteristics will fit into or frustrate the network. If both prerequisites are available/ positive the instrument will more likely be found to be legitimate and transparent, and consequently the compliance by its users will rise.
PHP7 INTERNATIONAL COMPARISON OF GENERIC MEDICINE PRICES
Simoens S Katholieke Universiteit Leuven, Leuven, Belgium OBJECTIVES: The introduction of generic price-regulated systems in many European countries, the trend towards international generic medicine companies, and competition from Indian companies emphasise the need to gain insight into international prices of generic medicines. The aim of this study is to compare generic medicine prices in ambulatory care in Belgium with prices in other countries in 2005. The price difference between original and generic medicines in Belgium is also elicited. METHODS: Data on ex-manufacturer prices of generic medicines of 15 molecules/strengths were derived from IMS Health. Belgian prices were compared with prices observed in Denmark, France, Germany, India, The Netherlands, Norway, Spain, Sweden and the UK. Comparability of pharmaceutical form was attained by limiting the analysis to medicines in immediate-release, oral, solid dosage forms. For each molecule/strength, the average price per standard unit weighted by volume of sales of all available package sizes and generic manufacturers was calculated. RESULTS: India and Scandinavian countries had the lowest ex-manufacturer prices of generic medicines of selected molecules/strengths. The 15 molecules/strengths were, on average, 63% cheaper in India than in Belgium. The average price across generic molecules/strengths in Belgium (0.206 €) was higher than the mean price across all countries (0.190 €). The highest average price levels were observed in France (0.254 €), The Netherlands (0.260 €) and Germany (0.269 €). Exmanufacturer prices of a specific generic molecule/strength varied between countries by a factor 3-36, depending on the molecule/ strength. The price difference between original and generic medicines generally ranged from -12% for simvastatin 20 mg to -62% for enalapril 5 mg in Belgium. CONCLUSION: Ex-manufacturer prices of selected generic medicines varied substantially between countries. India has emerged as a low-cost producer of generic medicines. The international price comparison reveals that there may be scope for reducing generic medicine prices in a number of countries.
